Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Lexapro Prescribers: Psychiatrists (US)

Articles with lock require a subscription to GLG News | Request a free trial
August 2, 2007
ADHD Medications Not a Cure, But a Start for Dysfunctional Kids
Analysis of: Studies Track Treatment Outcomes for Kids With ADHD | www.forbes.com
Author: GLG Expert Contributor
Studies tracking the behavioral outcomes of ADHD kids might appear to debunk the long-term benefits of ADHD medication.  However, this is not the case as a different perspective demonstrates.
August 2, 2007
Shire (SHPGY) May Have Another Winner, But This Will Take Some Convincing
Analysis of: Shire's New ADHD medication, VYVANSE(TM) (lisdexamfetamine dimesylate) Now Available in U.S. Pharmacies Nationwide | www.eurekalert.org
Author: GLG Expert Contributor
VYVANSE, a pro-drug of dextroamphetamine, may well have the markings of a winner in the realm of ADHD medication for several reasons, but it may also prove a hard sell.
August 2, 2007
Bristol-Myers Squibb(BMY) Has Another Winner with sNDA for Depression(?)
Analysis of: ABILIFY(R) (aripiprazole) Supplemental New Drug Application Receives Priority Review by U.S. Food And Drug Administration for Adjunctive Treatment in Adults With Major Depressive Disorder | www.pipelinereview.com
Author: GLG Expert Contributor
The sNDA for Bristol-Myers Squibb's(BMY) Abilify for depression will most likely result in approval for this new indication. Market success will be determined by several factors.
July 24, 2007
Key Determinant which treatment works best for which particular patient
Analysis of: Studies Track Treatment Outcomes for Kids With ADHD | www.forbes.com
Author: GLG Expert Contributor
1. These are landmark studies helping us better understand the long-term outcome of children with ADHD 2. Recognize that even with treatment the symptoms do not go away 3. Have to take a medical approach analogous to other medical conditions, e.g, diabetes where biologic intervention (e.g, insulin)...
July 24, 2007
More questions than answers raised by this report
Analysis of: UK Regulator: 1 Person in 10 on Acomplia Experiences Psychiatric Side Effects | www.acompliareport.com
Author: GLG Expert Contributor
1. These type of reports can be concerning but are countered by rates of 'psychiatric events/reactions' in the general community. 2. There are key questions, e.g, how many dieters had diagnosed (or undiagnosed) psychiatric conditions? 3. Tougher warnings can be good if it warns physicians and patients...
July 13, 2007
Antidepressant Backlash Can Be Depressing for Patients, Psychiatrists and Big Pharma
Analysis of: The Unmedicated Mind: Backlash against antidepressants is fueling new interest in alternative treatments | online.wsj.com
Author: GLG Expert Contributor
As the Antidepressant Backash gathers steam, fueled by FDA warnings, the media, and alternative providers, what are the implications for our patients.  The worst case scenario may be quite grim.
July 13, 2007
Generic Epilepsy Drugs: Is the Price Too High for Less Expensive Drugs?
Analysis of: Industry Fights Switch to Generics for Epilepsy | online.wsj.com
Author: GLG Expert Contributor
Third party payors savour the prospect of generic drugs.  However, with some medical conditions generic substitution is questionable.  This issue merits careful consideration in the case of epilepsy.
July 13, 2007
Johnson & Johnson(JNJ) Proves its "Staying Power" with New Sex Drug
Analysis of: J & J Hasn't Given Up on Sex Pill for Men | biz.yahoo.com
Author: GLG Expert Contributor
Johnson and Johnson is persistent in trying to get approval for its premature ejaculation drug, dapoxetine.  Is the drug really that effective and is it better than other SSRI's for this purpose.  Will it fly with European regulators and will men (and women?) want it.
July 13, 2007
FDA Advisory Leads to A Disturbing Trend: Patients Undiagnosed and Untreated
Analysis of: Pediatric SSRI Use, Depression Diagnosis Dropped After FDA Advisory | www.medscape.com
Author: GLG Expert Contributor
The recently described study showing a decrease in both the diagnosis and the treatment of pediatric depression is quite disturbing. The reasons for this drop-off relate to ways in which the prescribing community reacts to FDA warnings.
July 12, 2007
Very exciting new lead in ADHD research
Analysis of: Shire Receives Approvable Letter from FDA for INTUNIV(TM) (guanfacine) Extended Release, a Nonstimulant for the Treatment of ADHD | www.pipelinereview.com
Author: GLG Expert Contributor
1. While 70% of ADHD patients respond to stimulants and Strattera, 30% do not; thus, a large population who need new treatment approaches 2. Extended release preparation offers significant advantages 3. This medication has shown some efficacy in controlled study with tics/tourettes-often comorbid with...

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Next61 to 70 of 157

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-02T09:45:16.440